Investor Presentaiton
Investor Presentation
First nine months of 2018
Slide 6
Sales growth of 4% measured in local currencies mainly
driven by Victoza®, OzempicⓇ and SaxendaⓇ
-
Sales as reported – first nine months of 2018
Other
Growth
disorders biopharmaceuticals
(1%)
(14%)
%
Haemophilia 6%
(8%) 9%
Obesity
42%
3%
81%
Growth break down
Local currencies
-
Growth
first nine months of 2018
Share of growth
(7%)
3%
(2%)
1%
(2%)
Long-acting insulin¹
Premix insulin²
Fast-acting insulin³
(7%)
Human insulin
1%
2%
Diabetes care
(2%)
Total insulin
(1%)
(9%)
GLP-14
18%
84%
Other diabetes care5
2%
1%
Total diabetes care
4%
76%
Obesity (SaxendaⓇ)
53%
28%
Diabetes care and obesity total
5%
104%
Haemophilia
(3%)
(6%)
Growth disorders (NorditropinⓇ)
5%
6%
Other biopharmaceuticals?
(10%)
(4%)
Biopharmaceuticals
(1%)
4%
(4%)
100%
Sales of DKK 82.1 billion (2%)
changing
diabetes
Total
1 Comprises Tresiba®, XultophyⓇ and LevemirⓇ: 2 Comprises RyzodegⓇ and NovoMix®
3 Comprises FiaspⓇ and NovoRapidⓇ; 4 Comprises VictozaⓇ and Ozempic®
5 Primarily NovoNorm® and needles; 6 Comprises NovoSeven®, NovoEight®
NovoThirteenⓇ and Refixia®; 7 Primarily Vagifem® and Activelle®View entire presentation